Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

350 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer.
Abad A, Carrato A, Navarro M, Sastre J, Cervantes A, Antón A, Martinez-Villacampa M, Marcuello E, Massutí B, Aranda E, Manzano JL, Guallar JL, Diaz-Rubio E. Abad A, et al. Clin Colorectal Cancer. 2005 Mar;4(6):384-9. doi: 10.3816/ccc.2005.n.010. Clin Colorectal Cancer. 2005. PMID: 15807931 Clinical Trial.
Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
Sastre J, Marcuello E, Masutti B, Navarro M, Gil S, Antón A, Abad A, Aranda E, Maurel J, Valladares M, Maestu I, Carrato A, Vicent JM, Díaz-Rubio E; Cooperative Group for the Treatment of Digestive Tumors. Sastre J, et al. Among authors: abad a. J Clin Oncol. 2005 May 20;23(15):3545-51. doi: 10.1200/JCO.2005.03.004. J Clin Oncol. 2005. PMID: 15908665 Clinical Trial.
Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study.
Abad A, Massuti B, Antón A, Vega ME, Yuste AL, Marcuello E, Manzano JL, Alonso V, Carrato A, Martinez-Villacampa M, Tabernero J, Aranda E, Rivera F, Díaz-Rubio E; Spanish Cooperative Group for Digestive Tumor Therapy. Abad A, et al. Acta Oncol. 2008;47(2):286-92. doi: 10.1080/02841860701630259. Acta Oncol. 2008. PMID: 17957505 Clinical Trial.
Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer.
Martinez-Balibrea E, Abad A, Aranda E, Sastre J, Manzano JL, Díaz-Rubio E, Gómez-España A, Aparicio J, García T, Maestu I, Martínez-Cardús A, Ginés A, Guino E; Spanish Group for the Treatment of Digestive Tumours. Martinez-Balibrea E, et al. Among authors: abad a. Eur J Cancer. 2008 Jun;44(9):1229-37. doi: 10.1016/j.ejca.2008.03.025. Epub 2008 Apr 28. Eur J Cancer. 2008. PMID: 18448328 Clinical Trial.
Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism.
Font A, Sánchez JM, Tarón M, Martinez-Balibrea E, Sánchez JJ, Manzano JL, Margelí M, Richardet M, Barnadas A, Abad A, Rosell R. Font A, et al. Among authors: abad a. Invest New Drugs. 2003 Nov;21(4):435-43. doi: 10.1023/a:1026251202137. Invest New Drugs. 2003. PMID: 14586211 Clinical Trial.
Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan.
Martinez-Balibrea E, Manzano JL, Martinez-Cardus A, Moran T, Cirauqui B, Catot S, Taron M, Abad A. Martinez-Balibrea E, et al. Among authors: abad a. Oncol Rep. 2007 Mar;17(3):637-45. Oncol Rep. 2007. PMID: 17273745
350 results